These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24457369)

  • 1. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.
    Julien S; Biesemeier A; Taubitz T; Schraermeyer U
    Br J Ophthalmol; 2014 Jun; 98(6):813-25. PubMed ID: 24457369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys.
    Ludinsky M; Christner S; Su N; Taubitz T; Tschulakow A; Biesemeier A; Julien-Schraermeyer S; Schraermeyer U
    Graefes Arch Clin Exp Ophthalmol; 2016 Jun; 254(6):1117-25. PubMed ID: 27106625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of bevacizumab in retina and choroid after intravitreal injection into monkey eyes.
    Schraermeyer U; Julien S
    Expert Opin Biol Ther; 2013 Feb; 13(2):157-67. PubMed ID: 23190450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.
    Tschulakow A; Christner S; Julien S; Ludinsky M; van der Giet M; Schraermeyer U
    PLoS One; 2014; 9(11):e113701. PubMed ID: 25415380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation.
    Blaauwgeers HG; Holtkamp GM; Rutten H; Witmer AN; Koolwijk P; Partanen TA; Alitalo K; Kroon ME; Kijlstra A; van Hinsbergh VW; Schlingemann RO
    Am J Pathol; 1999 Aug; 155(2):421-8. PubMed ID: 10433935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
    Klettner A; Recber M; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penetration of bevacizumab through the retina after intravitreal injection in the monkey.
    Heiduschka P; Fietz H; Hofmeister S; Schultheiss S; Mack AF; Peters S; Ziemssen F; Niggemann B; Julien S; Bartz-Schmidt KU; Schraermeyer U;
    Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2814-23. PubMed ID: 17525217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H; Shah CP; Weber M; Heier JS
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
    Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid.
    Kim IK; Husain D; Michaud N; Connolly E; Lane AM; Durrani K; Hafezi-Moghadam A; Gragoudas ES; O'Neill CA; Beyer JC; Miller JW
    Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):357-63. PubMed ID: 16384985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro induction of protein complexes between bevacizumab, VEGF-A¹⁶⁵ and heparin: explanation for deposits observed on endothelial veins in monkey eyes.
    Julien S; Biesemeier A; Schraermeyer U
    Br J Ophthalmol; 2013 Apr; 97(4):511-7. PubMed ID: 23355530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal anatomical response of retinal-choroidal anastomosis to anti-vascular endothelial growth factor therapy.
    Querques G; Rousseau A; Forte R; Scemama C; Caillaux V; Querques L; Souied EH
    Retina; 2012 Mar; 32(3):458-67. PubMed ID: 21926939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
    Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
    Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab.
    Peters S; Heiduschka P; Julien S; Ziemssen F; Fietz H; Bartz-Schmidt KU; ; Schraermeyer U
    Am J Ophthalmol; 2007 Jun; 143(6):995-1002. PubMed ID: 17449002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and histological findings after intravitreal injection of bevacizumab (Avastin) in a porcine model of choroidal neovascularization.
    Lassota N; Prause JU; Scherfig E; Kiilgaard JF; la Cour M
    Acta Ophthalmol; 2010 May; 88(3):300-8. PubMed ID: 19416113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
    Schnichels S; Hagemann U; Januschowski K; Hofmann J; Bartz-Schmidt KU; Szurman P; Spitzer MS; Aisenbrey S
    Br J Ophthalmol; 2013 Jul; 97(7):917-23. PubMed ID: 23686000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
    Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
    Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.